Ironwood Non Current Liabilities Other from 2010 to 2025
| IRWD Stock | USD 1.41 0.05 3.42% |
Non Current Liabilities Other | First Reported 2011-06-30 | Previous Quarter 34.7 M | Current Value 39.8 M | Quarterly Volatility 27.9 M |
Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 20.8 M or Total Revenue of 240.3 M, as well as many indicators such as Price To Sales Ratio of 1.91, Capex To Depreciation of 0.19 or Inventory Turnover of 0.97. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
Ironwood | Non Current Liabilities Other |
Latest Ironwood Pharmaceuticals' Non Current Liabilities Other Growth Pattern
Below is the plot of the Non Current Liabilities Other of Ironwood Pharmaceuticals over the last few years. It is Ironwood Pharmaceuticals' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ironwood Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Other | 10 Years Trend |
|
Non Current Liabilities Other |
| Timeline |
Ironwood Non Current Liabilities Other Regression Statistics
| Arithmetic Mean | 14,480,042 | |
| Geometric Mean | 5,598,842 | |
| Coefficient Of Variation | 133.25 | |
| Mean Deviation | 14,514,683 | |
| Median | 9,766,000 | |
| Standard Deviation | 19,294,971 | |
| Sample Variance | 372.3T | |
| Range | 70.9M | |
| R-Value | 0.27 | |
| Mean Square Error | 369.5T | |
| R-Squared | 0.07 | |
| Significance | 0.31 | |
| Slope | 1,099,790 | |
| Total Sum of Squares | 5584.4T |
Ironwood Non Current Liabilities Other History
About Ironwood Pharmaceuticals Financial Statements
Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Other | 25.6 M | 26.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share 0.01 | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.